瑞格非尼 Regorafenib Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities.

舒尼替尼 Sunitinib It is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate salt was approved by the FDA for the treatment of renal cell carcinoma.

Imatinib is a tyrosine kinase inhibitor with antineoplastic activity. It binds to an intracellular pocket located within tyrosine kinases (TK).

色瑞替尼 Ceritinib Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC).

克唑替尼 Crizotinib Crizotinib, also known as PF-02341066, is an orally bioavailable agent belonging to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors